**Name of Journal: *World Journal of Gastrointestinal Pathophysiology***

**ESPS Manuscript NO: 20912**

**Manuscript Type: Review**

Upper gastrointestinal bleeding risk scores: Who, when and why?

Monteiro S *et al.* Upper gastrointestinal bleeding risk scores

Sara Monteiro, Tiago Cúrdia Gonçalves, Joana Magalhães, José Cotter

Sara Monteiro, Tiago Cúrdia Gonçalves, Joana Magalhães, José Cotter, Department of Gastroenterology, Hospital Senhora da Oliveira-Guimarães, Creixomil, 4835-044 Guimarães, Portugal

Author contributions: Monteiro S performed the literature search; Monteiro S, Gonçalves TC and Magalhães J wrote the paper; Cotter J designed and conducted the manuscript, critically revised the paper and finally approved the version to be submitted. All authors read and approved the final paper.

**Conflict-of-interest** **statement:** The authors have no conflict of interest to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** Sara Monteiro, MD, Department of Gastroenterology, Hospital Senhora da Oliveira-Guimarães, Rua dos Cutileiros, Creixomil, 4835-044 Guimarães, Portugal. sara.s.o.monteiro@gmail.com

**Telephone**: +351-25-3540330

**Fax**: +351-25-3513592

**Received:** June 26, 2015

**Peer-review started:** June 26, 2015

**First decision:** August 3, 2015

**Revised:** October 14, 2015

**Accepted:** December 9, 2015

**Article in press:**

**Published online:**

Abstract

Upper gastrointestinal bleeding (UGIB) remains a significant cause of hospital admission. In order to stratify patients according to the risk of the complications, such as rebleeding or death, and to predict the need of clinical intervention, several risk scores have been proposed and their use consistently recommended by international guidelines. The use of risk scoring systems in early assessment of patients suffering from UGIB may be useful to distinguish high-risks patients, who may need clinical intervention and hospitalization, from low risk patients with a lower chance of developing complications, in which management as outpatients can be considered. Although several scores have been published and validated for predicting different outcomes, the most frequently cited ones are the Rockall score and the Glasgow Blatchford score (GBS). While Rockall score, which incorporates clinical and endoscopic variables, has been validated to predict mortality, the GBS, which is based on clinical and laboratorial parameters, has been studied to predict the need of clinical intervention. Despite the advantages previously reported, their use in clinical decisions is still limited. This review describes the different risk scores used in the UGIB setting, highlights the most important research, explains why and when their use may be helpful, reflects on the problems that remain unresolved and guides future research with practical impact.

**Key words:** Upper gastrointestinal bleeding; Risk scores; Risk assessment; Rockall score; Glasgow blatchford score

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Upper gastrointestinal bleeding (UGIB) remains a significant cause of hospital admission. In order to stratify patients according to the risk of complications, such as rebleeding or death, and to predict the need of clinical intervention, several risk scores have been proposed and their use consistently recommended by international guidelines.This review describes the different risk scores used in the UGIB setting, highlights the most important research, explains why and when their use may be helpful, reflects on the problems that remain unresolved and guides future research with practical impact.

Monteiro S, Gonçalves TC, Magalhães J, Cotter J. Upper gastrointestinal bleeding risk scores: Who, when and why? *World J Gastrointest Pathophysiol* 2015; In press

**INTRODUCTION**

Acute upper gastrointestinal bleeding (UGIB) remains a common cause of visits to the Emergency Department, with an estimated incidence of about 100 per 100000 hospitalizations[[1](#_ENREF_1)], and being associated to significant morbidity, 30 d mortality and health-care costs[[2](#_ENREF_2),[3](#_ENREF_3)].

Many risk factors are known to influence the outcome in UGIB setting. Age, comorbidities, presence of shock, endoscopic diagnosis, haemoglobin values at the time, ulcers’ size, stigmata of recent haemorrhage and need for a blood transfusion have all been described as significant risk factors for rebleeding and death[[4-8](#_ENREF_4)].

Patients suffering from UGIB are generally admitted for observation with or without upper endoscopy. However, emergency endoscopy is not continuously available in many hospitals. An United Kingdom audit of 6750 patients suffering from UGIB has revealed that only 52% of the hospitals had an out-of-hours endoscopy service and only 50% patients received endoscopy within 24 h[[9](#_ENREF_9)].

In order to stratify the risk of complications, rebleeding, need of clinical intervention or death, several clinical scores are in use. Although recommended in the prevailing guidelines[[10](#_ENREF_10),[11](#_ENREF_11)] they are erratically applied in the clinical practice. To encourage the use of a risk score in the context of UGIB, it should be easy to calculate, contain easy access variables, have high accuracy in predicting relevant outcomes and distinguish low-risk from high-risk patients.

The purpose of this paper is to describe the different risk scores already in use, explain why and when they may be useful, reflect on their limitations in clinical practice and direct future investigations. Since the majority of the literature is limited to non-variceal upper gastrointestinal bleeding (NVUGIB), this review article will focus on such condition.

**UPPER GI BLEEDING RISK SCORES – WHO?**

From the different UGIB risk scores described, three main groups can be established: The scores only require endoscopic parameters, those that incorporate clinical and endoscopic parameters and those based solely on clinical parameters.

***Score with endoscopic variables only***

Forrest classification is based on endoscopic findings of an ulcer and is still useful to stratify patients into high- and low-risk categories in terms of rebleeding[[12](#_ENREF_12)].

The Forrest classification divides ulcers in six different categories, depending on the endoscopic findings. High risk lesions include those characterized by spurting haemorrhages (Forrest Ia), oozing haemorrhages (Forrest Ib), nonbleeding visible vessels (Forrest IIa), adherent clots (Forrest IIb). Low risk lesions include haematin on the ulcer base (Forrest IIc), and clean ulcer base (Forrest III).

Forrest Ia, Ib and IIa lesions require endoscopic treatment. For the ulcers with adherent clots (Forrest IIb) clot removal should be attempted by vigorous irrigation and should be treated according to the underlying lesion[[13](#_ENREF_13),[14](#_ENREF_14)].

***Clinical and endoscopic scores***

The most cited score incorporating clinical and endoscopic elements is the Rockall score. However, other scores such as the Baylor Bleeding Score (BBS), the Cedars-Sinai Medical Centre Predictive Index (CSMCPI), and more recently the PNED score have also been reported.

The Rockall score, which ranges from 0 to 11, was developed in 1996 to predict mortality due to UGIB[[15](#_ENREF_15)]. This score incorporates five variables: age, haemodynamic status, patient’s comorbidities, endoscopic diagnosis and presence of major stigmata of recent haemorrhage (Table 1). Patients’ stigmata of recent haemorrhage (blood in upper gastrointestinal tract, adherent clot, visible or spurting vessel) are recognised risk factors for rebleeding, surgery and death and are indications for endoscopic therapy[[16-18](#_ENREF_16)].

The BBS was originally developed for predicting rebleeding in patients with non-variceal haemorrhage[[19](#_ENREF_19)]. This scoring system, which ranges from 0 to 24, is divided into three parts: (1) a pre-endoscopy score based on age and number and severity of concurrent diseases; (2) an endoscopic score based on site and stigmata of bleeding; (3) a post-endoscopy score, which includes both the pre-endoscopy and the endoscopy score (Table 2).

The CSMCPI was developed as a guideline for determining the appropriate length of stay for patients admitted suffering from UGIB.Developed in 1996, by Hay and his colleagues, CSMCPI is based on four variables previously identified as independent predictors of outcome in patients suffering from UGIB : Endoscopic findings, symptoms at the time, haemodynamic instability, and number of comorbidities[[20](#_ENREF_20)]. The CSMCPI ranges from 0 to 11 (Table 3).

An Italian score of 10, the PNED score[[21](#_ENREF_21)], was developed and validated to predict 30 d mortality after non-variceal bleeding. The PNED score is based on ten variables, (8 clinical and 2 laboratorial), and ranges from 0 to 24 (Table 4).

***Scores with clinical variables only***

Several studies have tried to develop clinical scoring systems to stratify the patients’ risks based on the data immediately available at the time of the visit to the Emergency Department. These risk scores can be used to help physicians decide on the need for hospital admission, inpatient monitoring level and time for endoscopic evaluation.

Clinical risk scores may be useful to identify high-risk patients requiring immediate intervention and low-risk patients that can be safely discharged[[11](#_ENREF_11)]. The main clinical scores reported in the literature are the clinical Rockall score and the Glasgow-Blatchford Score (GBS). Other scores such as the AIMS65 and the T-score were only recently described.

The clinical Rockall score is calculated without the endoscopic findings[[15](#_ENREF_15),[22](#_ENREF_22)] (Table 1), and only includes 3 clinical variables: the patient’s age, the haemodynamic status, and the occurrence of a comorbid disease. A maximum score of 7 is possible.

The Glasgow-Blatchford Score incorporates 8 clinical or laboratorial variables (heart rate, haemoglobin value, blood urea nitrogen, systolic blood pressure, melena occurrence, syncope, hepatic disease, or heart failure) (Table 5). The GBS ranges from 0 to 23, with higher scores indicating higher likelihood of a need for an endoscopic intervention.

Saltzman *et al*[[23](#_ENREF_23)] developed an acronymic risk score named AIMS65 which incorporates albumin level < 3.0 g/dL (A), international normalized ratio (INR) >1.5 (I), altered mental status (M), systolic blood pressure ≤ 90 mmHg (S), and age > 65 years (65) (Table 6).

An Italian study developed the T-score which included 4 clinical parameters commonly assessedin the UGIB setting: (1) general conditions (poor, intermediate, good), (2) pulse (< 90 beats/min, 90-110 beats/min, > 110 beats/min), (3) systolic blood pressure (< 90 mmHg, 90-110 mmHg, > 110 mmHg), and haemoglobin level (≤ 8 g/dL, 9-10 g/dL, > 10 g/dL)[[24](#_ENREF_24)] (Table 7).

Although some other non-endoscopic scores have been developed, they still present some limitations which preclude their use in the clinical practice. For example, the Cambridge score[[25](#_ENREF_25)], described by Cameron and colleagues, incorporates 14 clinical and laboratorial variables, but has not been externally validated. An American score based on artificial neural networks (ANN) has been assessed, not only as a means to predict endoscopic findings, but also for the need for endoscopic treatment in patients suffering from UGIB[[26](#_ENREF_26),[27](#_ENREF_27)]. However, it requires the inclusion of 27 of the patients’ variables and a specialized computer software for analysis.

**THE IMPORTANCE OF OUTCOMES**

***When should we use a risk score?***

Despite methodological and demographic differences, the outcomes evaluated in the different studies are relatively similar. However, when attempting to implement different scoring systems in clinical practice it is important to know the primary outcome variable that was measured in each developed study. A summary of the main outcomes of each score is listed in Table 8.

There is evidence that most of the mortality in patients suffering from NVUGIB is not directly related to bleeding[[3](#_ENREF_3)]. So, adding clinical variables to a risk score may increase its ability to predict a specific outcome.

The Rockall scoreshould be used as a tool for identifying patients with low risk of rebleeding and death according to the clinical and endoscopic risk factors. Patients with Rockall scores of less than or equal to 2 should be considered for management in the community. This score was prospectively derived from 4185 cases of UGIB over a 4 mo period in 1993 and was afterwards validated by the same investigators on the following year in 1625 cases from the same hospitals[[15](#_ENREF_15)]. A higher Rockall score indicates a higher risk of a poor outcome. In a prospective validation of this score, Rockall *et al*[[28](#_ENREF_28)]showed that the patients with a score of 2 or less (29.4% of the cohort) had a rebleeding rate of 4.3 % and a mortality rate of 0.1%, suggesting that such patients could have been safely managed in the outpatient setting.

The Rockall score has been prospectively and externally validated in different populations[[29-32](#_ENREF_29)]. Church and Palmer from Edinburgh proposed that the Rockall score could be used to predict rebleeding and death by doing a retrospective analysis of cases of peptic ulceration enrolled into two trials of endoscopic haemostasis. The authors showed a correlation between the Rockall score and mortality or rebleeding. Patients with scores of 8 or greater had a significantly poorer outcome[[33](#_ENREF_33)].

Several studies have shown that the Rockall score was closely correlated with the probability of death, but not so close to the chance of rebleeding[[30-32](#_ENREF_30),[34](#_ENREF_34),[35](#_ENREF_35)]. This observation may be partly explained by the fact that the Rockall score was originally developed for the prediction of mortality rather than for the prediction of rebleeding and also because not all patients received endoscopic therapy[[15](#_ENREF_15)].

The clinical Rockall score, without endoscopy, can be used to improve the quality of patients’ care by identifying those patients less likely to require intensive health care services and selecting them for endoscopic evaluation as outpatients, allowing substantial resource savings.

Tham *et al*[[22](#_ENREF_22)] reported that patients classified as low risk, *i.e.,* clinical Rockall score of 0, can be managed in the outpatient setting because these patients had no adverse outcomes and did not require transfusion.

Phang *et al*[[36](#_ENREF_36)] demonstrated that clinical Rockall may be helpful to determine the appropriate environment into which UGIB patients should be admitted. In this study 60.5% of the patients with a clinical Rockall score of < 4 (low risk) had a mortality rate of 3.2%, meaning that they could have been managed in a general ward. On the other hand, from the 39.5% of patients with a clinical Rockall score of ≥ 4 (high risk), the mortality had a rate of 22.4%, indicating that those patients should be admitted to an intensive care unit. However, Gralnek *et al*[[37](#_ENREF_37)]found that the complete rockall Score identified more low-risk patients than the clinical Rockall score.

Regarding peptic ulcer disease,BBS was initially proposed to predict rebleeding after endoscopic therapy, but was rarely used in the clinical practice. The original BBS study revealed that the cut-off of ≥ 11 had a sensitivity of 100% and a specificity of 79% for the prediction of rebleeding[[19](#_ENREF_19)]. The same authors who created this score had validated it prospectively in a cohort of 47 patients with bleeding peptic ulcer who had undergone endoscopic therapy[[38](#_ENREF_38)]. Twenty-six patients were categorized as high-risk and 19 as low-risk. The rebleeding rate for high-risk patients was 31% and 0% for low-risk patients.

The CSMCPI may help to select low-risk patients suitable for early discharge[[20](#_ENREF_20),[39](#_ENREF_39)].In the original study of Hay and collaborators[[20](#_ENREF_20)] patients with a CSMCPI of 3 were considered suitable for discharge within 24 h. 70% of UGIB patients (349 of 500) were considered as low-risk according to this cut-off. Complications occurred in 2 patients (0.6%) classified as low-risk. The routine use of the CSMCPI was associated with a reduced time of admission in 79% of all low-risk cases with a potential reduction of 2.1 bed-days per patient.

An italian study compared the three main endoscopy-based scores (CSMCPI, BBS and Rockall) and found out that the full Rockall score was superior in predicting mortality and rebleeding, particularly in low risk patients. In this study all scores were better at predicting mortality than rebleeding[[29](#_ENREF_29)].

Marmo *et al*[[21](#_ENREF_21)] developed the PNED scoreto predict 30 d mortality in patients suffering from acute NVUGB and validated it in a large cohort of patients. The PNED score is simple, reliable and accurate in identifying high-risk patients (score > 4 points) most likely to benefit from high levels of care and prevent death[[21](#_ENREF_21)]. In a previous study the PNED score was significantly more accurate than the Rockall score in predicting death in non-variceal bleeders. This score introduces the failure to perform endoscopic haemostasis as a variable. As a matter of fact, in a former study by the same authors, the impossibility to perform endoscopic therapy was the strongest predictor of a negative outcome, being thus associated with an 11-fold risk of death[[40](#_ENREF_40)].

The GBSshould be used to predict the need for treatment (blood transfusion, endoscopic therapy or surgical intervention). This clinical score was developed from a prospective cohort involving 1748 patients admitted for UGIH in 19 centres in Scotland[[41](#_ENREF_41)]. The greatest feature of the GBS is its ability to identify low-risk patients (GBS = 0) who do not need to be admitted into a hospital. With a high sensitivity and a high negative predictive value, the GBS indicates that almost all patients with a score equal to 0 can be safely discharged. In return, its positive predictive value remains low due to the low specificity (32%), significantly overestimating the risk of poor outcomes. A GBS of 0 was validated in the United Kingdom to safely discharge patients from Emergency Departments with suspected UGIB: 84 patients with a GBS equal to 0 were managed as outpatients without adverse events during the follow-up[[42](#_ENREF_42)]. In another United Kingdom study, 142 low-risk patients were managed without admission, and none of them required endoscopic intervention, blood transfusion or surgery. In this cohort of patients the 28 d mortality rate was 0[[43](#_ENREF_43)].

The GBS has been shown to be as good as the Rockall score in predicting the need for any intervention, namely the need for therapeutic endoscopy[[41](#_ENREF_41),[42](#_ENREF_42),[44-47](#_ENREF_44)]. The GBS has also been shown to be superior to the clinical Rockall score in identifying patients with suspected UGIB who have a low likelihood of an adverse clinical outcome (blood transfusion, endoscopic therapy, interventional radiology, surgery or 30 d mortality) and can be considered for early discharge[[48](#_ENREF_48)].

A multicentre study by Stanley *et al*[[47](#_ENREF_47)] found that the GBS was equivalent to both the full and clinical Rockall scores in predicting death. It was however superior to the clinical Rockall score, and similar to the full Rockall score in predicting the need for endoscopic therapy or surgical intervention and superior to both in predicting the need for blood transfusion. This late finding is similar in both scores, because the GBS includes the measurement of haemoglobin levels on admission.

A study by Ahn *et al*[[49](#_ENREF_49)] including patients with cancer who visited the Emergency Department, reported a greater accuracy of the GBS when compared to the Rockall score in predicting intervention in those patients.

Clinical variables such as liver disease, cardiovascular disease, presence of syncope, altered mental status and melena are susceptible to a subjective interpretation in GBS. Thus, a modified GBS could be used to eliminate subjective variables. A multicentre North American study reported that a modified GBS (without urea or syncope variables) was superior to the clinical Rockall score in predicting high risk of endoscopic stigmata in bleeding or rebleeding[[50](#_ENREF_50)]. Another North American study has only incorporated the four quantitative variables, eliminating the subjective variables such as history of syncope, presence of melena, liver disease, cardiovascular disease, as well as altered mental status. The reported conclusion is that the modified GBS performed as well as the full GBS while outperforming both clinical and endoscopic Rockall Scores for prediction of clinical outcomes[[51](#_ENREF_51)].

Some studies have suggested that the rate of identified low-risk patients could be increased by using a higher GBS cut-off value[[45](#_ENREF_45),[52-57](#_ENREF_52)] or by incorporating age as a variable[[52](#_ENREF_52),[58](#_ENREF_58)]. Stephens *et al*[[52](#_ENREF_52)] showed that there was a relationship between age and significant endoscopic findings in patients categorized as low-risk by GBS. In this study, patients with a GBS of ≤ 2, for each additional year of age, had the chance of a significant endoscopic finding increased by 8%. The authors concluded that using GBS ≤ 2 and age of less than 70 years to define low-risk patients allows 10.5% of patients suffering from UGIB to be safely managed in the community. Over a 5 year period of managing such patients without hospital admission, McLaughlin *et al*[[43](#_ENREF_43)] showed that any of them required endoscopic intervention, blood transfusion or surgery, and that the 28 d mortality was nil. A recent multicentre Danish study reported that a GBS cut-off value of ≤ 1 and an age modified low-risk version can be safely and effectively used to reduce unnecessary admissions for suspected UGIB[[55](#_ENREF_55)].

AIMS65 can potentially be used to predict in-hospital mortality, length of stay, and cost in patients with acute UGIB[[23](#_ENREF_23)]. When more than two components of AIMS65 are present, the mortality risk is considered to be high.

Hyett *et al*[[59](#_ENREF_59)] has reported the superiority of the AIMS65 score when compared to the **GBS** in predicting inpatient mortality, but inferiority in predicting the need for blood transfusion. In a north American retrospective study, the AIMS65 showed no ability to predict the need for blood transfusion[[60](#_ENREF_60)]. In a retrospective Japanese study, the AIMS65, but not the GBS, was considered an independent prognostic factor for poor overall survival[[61](#_ENREF_61)]. On the other hand, in a recent study by Jung *et al*[[62](#_ENREF_62)], the AIMS65was insufficient in predicting outcomes in peptic ulcer bleeding.

In a recent Turkish study, the GBS was found to have superior sensitivity when compared to the AIMS65 score in identifying patients who were not likely to require interventions, including emergency endoscopy[[63](#_ENREF_63)]. Such finding can be linked to the lower number of variables considered in this score. This score may not be able to detect low-risk patients with UGIB, but further studies are required.

Masaoka *et al*[[64](#_ENREF_64)] recently proposed an algorithm to assess the mortality risk, which consisted in applying the AIMS65 score after detecting low-risk patients with GBS ≤ 2.

The T-score can be used to triage patients who are likely to have high-risk endoscopic stigmata and therefore need intervention[[24](#_ENREF_24)]. It has the ability to predict high-risk endoscopic stigmata, rebleeding and mortality with an accuracy similar to the GBS[[65](#_ENREF_65)]. According to Tammaro and collaborators, a T-score of ≤ 6 was able to predict the presence of high risk endoscopic stigmata and the need for an early endoscopy with a specificity of 96% and a positive predictive value of 74.5%[[65](#_ENREF_65)].

Das *et al*[[26](#_ENREF_26)]showed that ANN was superior to the admission Rockall score and similar to the full Rockall score to predict the need for endoscopic intervention, but its applicability in clinical practice is complex and time consuming.

***Therapeutic decisions – why or why not should we use a risk score?***

The consensus opinion recommends the early use of risk stratification scores in patients suffering from UGIB[[10](#_ENREF_10),[11](#_ENREF_11),[13](#_ENREF_13)]. Many of these differ in the outcomes they were suggested for (risk of mortality, rebleeding and need for therapeutic intervention). However, in the era of increased outpatient management of UGIB, predicting the need for therapeutic intervention may be as useful as predicting rebleeding and death. Stratification risk systems could reduce the resources and costs without adversely influencing the patients’ outcomes[[66](#_ENREF_66)].

The greatest interest of clinical scores lies in their ability to identify patients at low risk of complications who are suitable for early discharge without endoscopy. There is considerable evidence from several geographical regions (both in the United Kingdom and around the world)[[41](#_ENREF_41),[42](#_ENREF_42),[44](#_ENREF_44),[46](#_ENREF_46),[48](#_ENREF_48),[56](#_ENREF_56)] that the GBS is an excellent risk assessment tool and accurately identifies patients with a low risk of requiring intervention or death. However, the best GBS cut-off for these situations is not clearly defined. Moreover, using a cut-off of 0 to predict low risk for adverse events has a practical limitation, since most of the patients who visit the Emergency Department with UGIB will score at least 1 point[[41](#_ENREF_41),[42](#_ENREF_42),[46](#_ENREF_46),[65](#_ENREF_65),[67](#_ENREF_67)]. Possible explanations for the reported cut-off variation are differences in the demographics characteristics, aetiology of UGIB, routine use of proton pump inhibitors before endoscopy and adherence to guidelines regarding the need for endoscopic therapy.

Although with high sensitivity to identify patients at high risk for developing the need for blood transfusion, endoscopic therapy, or surgical intervention, the GBS has a low specificity[[44](#_ENREF_44),[45](#_ENREF_45),[48](#_ENREF_48),[56](#_ENREF_56)[68](#_ENREF_68),[69](#_ENREF_69)] .

Advanced age is a risk factor for death[[70](#_ENREF_70)] and low-risk patients in general are younger than high-risk patients with UGIB. Despite not including age and being developed for predicting clinical intervention after UGIB detection, the GBS has proven to be equivalent to the Rockall score in predicting death[[47](#_ENREF_47)]. Nevertheless, the ability of the GBS to identify low-risk patients may be enhanced by incorporating age as a variable[[52](#_ENREF_52),[58](#_ENREF_58)].

Although there is greater consensus that certain endoscopic findings are associated with a high risk for adverse outcomes (*e.g.,* active bleeding or non-bleeding visible vessel), and other findings indicate a low risk for such outcomes (*e.g.,* clean-base ulcer, Mallory-Weiss tear), some controversy remains in what concerns the need of endoscopy as a component for early risk stratification at the initial patients’ triage[[71](#_ENREF_71)].

Almost all patients in the low risk group of the Rockall score had no stigmata of recent haemorrhage[[29](#_ENREF_29),[35](#_ENREF_35)] and in clinical practice decisions regarding patient length of stay, admission place (intensive care unit versus regular ward) and therapeutic decisions are usually made on the basis of endoscopic appearance rather than the Rockall score[[13](#_ENREF_13)]. The Forrest classification has shown a higher specificity and positive predictive value for the prediction of rebleeding and death when compared to other four scoring systems that were evaluated (the Rockall, the CSMCPI, the GBS and the BBS scores)[[34](#_ENREF_34)].

The responsibility for initial patient assessment lies on the Emergency Department staff who invariably are general physicians or surgeons and may be uncomfortable about discharging patients without an endoscopy. Thus, although the GBS has shown a great ability to detect patients with low risk of complications in the Emergency Department setting, an endoscopy continues to support the patient management. On the other hand, by adopting a policy of urgent endoscopies in all patients with acute UGIB, several patients will undergo an unnecessary urgent procedure.

Another important key question in the management of patients with UGIB is the timing of the endoscopy, even though the overall consensus suggests that it should be performed within 24 h from admission[[10](#_ENREF_10)]. Earlier endoscopy was not associated with a reduction in mortality or need for surgery. However, it was associated with an increased efficiency of care, a potential improvement in the control of haemorrhage in high-risk patients, and a reduction in the length of stay. All these factors support the routine use of early endoscopies, unless specific contraindications occur[72,[73](#_ENREF_73)].

The Rockall Score is unable to address this question, since it requires endoscopic findings. A retrospective study by Lim *et al*[[65](#_ENREF_65)] revealed that performing an endoscopy within 13 h for high-risk patients with a GBS of > 12 is associated with a reduced mortality[[74](#_ENREF_74)]. The timing of urgent endoscopy following an episode of UGIB may be also differentiated according to the simplified clinical T-score of ≤ 6.

The need for a therapeutic endoscopy may also be a subjective decision[[75](#_ENREF_75)] and a score that would equally help endoscopists in the decision to perform an urgent intervention is still warranted. Ideally, simple clinical scores could facilitate the identification of high-risk patients who could benefit from an early endoscopy with therapeutic intervention. Farooq *et al*[[76](#_ENREF_76)]reported that the use of clinical Rockall and GBS was less accurate than a clinical triage decision in predicting the need for endoscopic therapy. In the study by Attar *et al*[[67](#_ENREF_67)]*,* the GBS showed an equivalent sensitivity when compared to endoscopists (both 98%) in the detection of urgent upper endoscopy necessity. However, both GBS and endoscopists showed a very poor specificity, being unable to detect non urgent patients to endoscopy.

In a recent multicentre study, although clinical knowledge of the endoscopists (described as “gut feeling”) was an independent predictor for an adverse outcome, it had a lower sensitivity and a worst predictive power compared to prediction scores[[77](#_ENREF_77)].

The reasons for not using clinical scores may be that they are difficult to calculate and time consuming and do not add much information to the physician’s knowledge. Furthermore, no clinicians will feel comfortable in managing an elderly patient as an outpatient even if he has a GBS of 0. When there is clinical concern on avoiding admission in elderly patients, the use of an age modified GBS should be considered[[55](#_ENREF_55)].

In real life, patients may also take antiplatelet and anticoagulant medications that may further increase the rebleeding rate and mortality, an issue not addressed in most reported studies. However, the AIMS65 includes the INR as a risk factor and an INR > 1.5 has been shown to be independently associated with in-hospital mortality in acute NVUGIB in a recent multicentre UK national audit[[78](#_ENREF_78)].

The variables of AIMS65, with the exception of blood pressure, are different from those in the GBS. Albumin level and age may also contribute to the superiority of this score for the prediction of mortality[[59](#_ENREF_59)]. Furthermore, it has advantages over the existing risk scores, including the fact of being easy to remember and lacking the subjectivity in its calculation.

All scores seem to have lower performance in high-risk patients. Most clinical scores have poor specificity, possibly leading to unjustified upper endoscopies in the emergency context. However, the sensitivity of these scores may be likely more important than specificity, since they may help in physician’s decisions, ensuring that any patient who may have a poor prognosis is discharged.

Extending the definition of low-risk patient may lead to outpatient management of patients who may actually need clinical intervention. Indeed, the cut-off value for considering patients to be at low or high risk may depend on local healthcare assistance and outpatient support and therefore needs to be carefully assessed in different populations.

Personalized medicine can help in stratification of patients according to biomarkers and guide optimal treatment and prevention. The molecular pathological epidemiology (MPE) is a recently established interdisciplinary and transdisciplinary field, which emerged from the complex relationship between etiological factors, molecular alterations, and disease evolution[[79](#_ENREF_79),[80](#_ENREF_80)]. MPE may stratify UGIB into different subtypes according to the pathogenic mechanisms, enabling a more efficient and individualized approach.

To date, most of MPE research is applied to cancer[[81](#_ENREF_81),[82](#_ENREF_82)], but this approach may also be important to UGIB and further investigation is needed to evaluate its contribution.

**CONCLUSION**

We believe that the value of risk scores in predicting the outcomes in acute UGIB has been proven far beyond any scepticism. Routine use of scoring systems by unspecialized medical staff could save lives, alert to the severity of a patient’s condition and lead to an immediate referral. Furthermore, it could be an auxiliary tool for endoscopists that are often asked to perform an urgent endoscopy and have to decide whether the procedure should be done immediately or delayed up to 24 h. Endoscopic based scores can determine intensive care strategies, endoscopic therapy and length of hospitalization. As a means to predict low risk patients amenable to an early discharge and outpatient management, the Rockall and GBS are the two most commonly used and recommended risk stratification systems[[13](#_ENREF_13)].

T-score, recently described, can potentially be useful to predict high-risk endoscopic stigmata and the need of early intervention[[65](#_ENREF_65)]. We recommend the use of non-endoscopic scores as the pre-endoscopic Rockall score or the GBS, as a decision tools for patients with acute UGIB. The scores may be useful when endoscopy are not available in the emergency department. A patient with Rockall score or the GBS equal to 0 can be safely discharged.

Moreover, we also advocate early endoscopy (within 12 to 24 h of admission) and early discharge of patients with low risk lesions or low post-endoscopic risk scores (*e.g.,* post-endoscopic Rockall score ≤ 2).

Theoretically, the perfect score would be applicable in the two different stages of the patient’s assessment, pre- and post-endoscopy, with excellent accuracy for the main outcomes in the context of UGIB: Rebleeding, death, and need of clinical intervention. However, since both scores have reached sufficient levels of efficiency that enable their safe employment in clinical practice, and until further research proves this premise, endoscopists should continue to rely on their “gut feeling” and on all the endoscopic findings as the key factors to guide their therapeutic decisions in patients with UGIB.

**REFERENCES**

1 **Longstreth GF**. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. *Am J Gastroenterol* 1995; **90**: 206-210 [PMID: 7847286]

2 **Lanas A**, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. *Am J Gastroenterol* 2009; **104**: 1633-1641 [PMID: 19574968 DOI: 10.1038/ajg.2009.164]

3 **Sung JJ**, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. *Am J Gastroenterol* 2010; **105**: 84-89 [PMID: 19755976 DOI: 10.1038/ajg.2009.507]

4 **Chiu PW**, Ng EK. Predicting poor outcome from acute upper gastrointestinal hemorrhage. *Gastroenterol Clin North Am* 2009; **38**: 215-230 [PMID: 19446255 DOI: 10.1016/j.gtc.2009.03.009]

5 **Klebl F**, Bregenzer N, Schöfer L, Tamme W, Langgartner J, Schölmerich J, Messmann H. Risk factors for mortality in severe upper gastrointestinal bleeding. *Int J Colorectal Dis* 2005; **20**: 49-56 [PMID: 15322836 DOI: 10.1007/s00384-004-0624-2]

6 **Zimmerman J**, Siguencia J, Tsvang E, Beeri R, Arnon R. Predictors of mortality in patients admitted to hospital for acute upper gastrointestinal hemorrhage. *Scand J Gastroenterol* 1995; **30**: 327-331 [PMID: 7610347]

7 **Imperiale TF**, Dominitz JA, Provenzale DT, Boes LP, Rose CM, Bowers JC, Musick BS, Azzouz F, Perkins SM. Predicting poor outcome from acute upper gastrointestinal hemorrhage. *Arch Intern Med* 2007; **167**: 1291-1296 [PMID: 17592103 DOI: 10.1001/archinte.167.12.1291]

8 **Nahon S**, Hagège H, Latrive JP, Rosa I, Nalet B, Bour B, Faroux R, Gower P, Arpurt JP, Denis J, Henrion J, Rémy AJ, Pariente A. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. *Endoscopy* 2012; **44**: 998-1008 [PMID: 23108771 DOI: 10.1055/s-0032-1310006]

9 **Hearnshaw SA**, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. *Gut* 2010; **59**: 1022-1029 [PMID: 20357318 DOI: 10.1136/gut.2008.174599]

10 **Barkun AN**, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med* 2010; **152**: 101-113 [PMID: 20083829 DOI: 10.7326/0003-4819-152-2-201001190-00009]

11 **Dworzynski K**, Pollit V, Kelsey A, Higgins B, Palmer K. Management of acute upper gastrointestinal bleeding: summary of NICE guidance. *BMJ* 2012; **344**: e3412 [PMID: 22695897 DOI: 10.1136/bmj.e3412]

12 **Forrest JA**, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. *Lancet* 1974; **2**: 394-397 [PMID: 4136718]

13 **Laine L**, Jensen DM. Management of patients with ulcer bleeding. *Am J Gastroenterol* 2012; **107**: 345-60; quiz 361 [PMID: 22310222 DOI: 10.1038/ajg.2011.480]

14 **Holster IL**, Kuipers EJ. Update on the endoscopic management of peptic ulcer bleeding. *Curr Gastroenterol Rep* 2011; **13**: 525-531 [PMID: 21918857 DOI: 10.1007/s11894-011-0223-7]

15 **Rockall TA**, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut* 1996; **38**: 316-321 [PMID: 8675081]

16 **Lin HJ**, Perng CL, Lee FY, Lee CH, Lee SD. Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study. *Gut* 1994; **35**: 1389-1393 [PMID: 7959193]

17 **Laine L**, Peterson WL. Bleeding peptic ulcer. *N Engl J Med* 1994; **331**: 717-727 [PMID: 8058080 DOI: 10.1056/nejm199409153311107]

18 **Laine L**, Cohen H, Brodhead J, Cantor D, Garcia F, Mosquera M. Prospective evaluation of immediate versus delayed refeeding and prognostic value of endoscopy in patients with upper gastrointestinal hemorrhage. *Gastroenterology* 1992; **102**: 314-316 [PMID: 1727765]

19 **Saeed ZA**, Winchester CB, Michaletz PA, Woods KL, Graham DY. A scoring system to predict rebleeding after endoscopic therapy of nonvariceal upper gastrointestinal hemorrhage, with a comparison of heat probe and ethanol injection. *Am J Gastroenterol* 1993; **88**: 1842-1849 [PMID: 8237930]

20 **Hay JA**, Lyubashevsky E, Elashoff J, Maldonado L, Weingarten SR, Ellrodt AG. Upper gastrointestinal hemorrhage clinical--guideline determining the optimal hospital length of stay. *Am J Med* 1996; **100**: 313-322 [PMID: 8629677]

21 **Marmo R**, Koch M, Cipolletta L, Capurso L, Grossi E, Cestari R, Bianco MA, Pandolfo N, Dezi A, Casetti T, Lorenzini I, Germani U, Imperiali G, Stroppa I, Barberani F, Boschetto S, Gigliozzi A, Gatto G, Peri V, Buzzi A, Della Casa D, Di Cicco M, Proietti M, Aragona G, Giangregorio F, Allegretta L, Tronci S, Michetti P, Romagnoli P, Piubello W, Ferri B, Fornari F, Del Piano M, Pagliarulo M, Di Mitri R, Trallori G, Bagnoli S, Frosini G, Macchiarelli R, Sorrentini I, Pietrini L, De Stefano S, Ceglia T, Chiozzini G, Salvagnini M, Di Muzio D, Rotondano G. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. *Am J Gastroenterol* 2010; **105**: 1284-1291 [PMID: 20051943 DOI: 10.1038/ajg.2009.687]

22 **Tham TC**, James C, Kelly M. Predicting outcome of acute non-variceal upper gastrointestinal haemorrhage without endoscopy using the clinical Rockall Score. *Postgrad Med J* 2006; **82**: 757-759 [PMID: 17099097 DOI: 10.1136/pmj.2006.048462]

23 **Saltzman JR**, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. *Gastrointest Endosc* 2011; **74**: 1215-1224 [PMID: 21907980 DOI: 10.1016/j.gie.2011.06.024]

24 **Tammaro L**, Di Paolo MC, Zullo A, Hassan C, Morini S, Caliendo S, Pallotta L. Endoscopic findings in patients with upper gastrointestinal bleeding clinically classified into three risk groups prior to endoscopy. *World J Gastroenterol* 2008; **14**: 5046-5050 [PMID: 18763288]

25 **Cameron EA**, Pratap JN, Sims TJ, Inman S, Boyd D, Ward M, Middleton SJ. Three-year prospective validation of a pre-endoscopic risk stratification in patients with acute upper-gastrointestinal haemorrhage. *Eur J Gastroenterol Hepatol* 2002; **14**: 497-501 [PMID: 11984147]

26 **Das A**, Ben-Menachem T, Farooq FT, Cooper GS, Chak A, Sivak MV, Wong RC. Artificial neural network as a predictive instrument in patients with acute nonvariceal upper gastrointestinal hemorrhage. *Gastroenterology* 2008; **134**: 65-74 [PMID: 18061180 DOI: 10.1053/j.gastro.2007.10.037]

27 **Rotondano G**, Cipolletta L, Grossi E, Koch M, Intraligi M, Buscema M, Marmo R. Artificial neural networks accurately predict mortality in patients with nonvariceal upper GI bleeding. *Gastrointest Endosc* 2011; **73**: 218-26, 226.e1-2 [PMID: 21295635 DOI: 10.1016/j.gie.2010.10.006]

28 **Rockall TA**, Logan RF, Devlin HB, Northfield TC. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. *Lancet* 1996; **347**: 1138-1140 [PMID: 8609747]

29 **Camellini L**, Merighi A, Pagnini C, Azzolini F, Guazzetti S, Scarcelli A, Manenti F, Rigo GP. Comparison of three different risk scoring systems in non-variceal upper gastrointestinal bleeding. *Dig Liver Dis* 2004; **36**: 271-277 [PMID: 15115340 DOI: 10.1016/j.dld.2003.10.017]

30 **Vreeburg EM**, Terwee CB, Snel P, Rauws EA, Bartelsman JF, Meulen JH, Tytgat GN. Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. *Gut* 1999; **44**: 331-335 [PMID: 10026316]

31 **Enns RA**, Gagnon YM, Barkun AN, Armstrong D, Gregor JC, Fedorak RN. Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting. *World J Gastroenterol* 2006; **12**: 7779-7785 [PMID: 17203520]

32 **Church NI**, Dallal HJ, Masson J, Mowat NA, Johnston DA, Radin E, Turner M, Fullarton G, Prescott RJ, Palmer KR. Validity of the Rockall scoring system after endoscopic therapy for bleeding peptic ulcer: a prospective cohort study. *Gastrointest Endosc* 2006; **63**: 606-612 [PMID: 16564860 DOI: 10.1016/j.gie.2005.06.042]

33 **Church NI**, Palmer KR. Relevance of the Rockall score in patients undergoing endoscopic therapy for peptic ulcer haemorrhage. *Eur J Gastroenterol Hepatol* 2001; **13**: 1149-1152 [PMID: 11711769]

34 **Kim BJ**, Park MK, Kim SJ, Kim ER, Min BH, Son HJ, Rhee PL, Kim JJ, Rhee JC, Lee JH. Comparison of scoring systems for the prediction of outcomes in patients with nonvariceal upper gastrointestinal bleeding: a prospective study. *Dig Dis Sci* 2009; **54**: 2523-2529 [PMID: 19104934 DOI: 10.1007/s10620-008-0654-7]

35 **Bessa X**, O'Callaghan E, Ballesté B, Nieto M, Seoane A, Panadès A, Vazquez DJ, Andreu M, Bory F. Applicability of the Rockall score in patients undergoing endoscopic therapy for upper gastrointestinal bleeding. *Dig Liver Dis* 2006; **38**: 12-17 [PMID: 16314150 DOI: 10.1016/j.dld.2005.05.012]

36 **Phang TS**, Vornik V, Stubbs R. Risk assessment in upper gastrointestinal haemorrhage: implications for resource utilisation. *N Z Med J* 2000; **113**: 331-333 [PMID: 11008609]

37 **Gralnek IM**, Dulai GS. Incremental value of upper endoscopy for triage of patients with acute non-variceal upper-GI hemorrhage. *Gastrointest Endosc* 2004; **60**: 9-14 [PMID: 15229418]

38 **Saeed ZA**, Ramirez FC, Hepps KS, Cole RA, Graham DY. Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. *Gastrointest Endosc* 1995; **41**: 561-565 [PMID: 7672549]

39 **Garripoli A**, Mondardini A, Turco D, Martinoglio P, Secreto P, Ferrari A. Hospitalization for peptic ulcer bleeding: evaluation of a risk scoring system in clinical practice. *Dig Liver Dis* 2000; **32**: 577-582 [PMID: 11142555]

40 **Marmo R**, Koch M, Cipolletta L, Capurso L, Pera A, Bianco MA, Rocca R, Dezi A, Fasoli R, Brunati S, Lorenzini I, Germani U, Di Matteo G, Giorgio P, Imperiali G, Minoli G, Barberani F, Boschetto S, Martorano M, Gatto G, Amuso M, Pastorelli A, Torre ES, Triossi O, Buzzi A, Cestari R, Della Casa D, Proietti M, Tanzilli A, Aragona G, Giangregorio F, Allegretta L, Tronci S, Michetti P, Romagnoli P, Nucci A, Rogai F, Piubello W, Tebaldi M, Bonfante F, Casadei A, Cortini C, Chiozzini G, Girardi L, Leoci C, Bagnalasta G, Segato S, Chianese G, Salvagnini M, Rotondano G. Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: a multicenter study. *Am J Gastroenterol* 2008; **103**: 1639-147; quiz 1648 [PMID: 18564127 DOI: 10.1111/j.1572-0241.2008.01865.x]

41 **Blatchford O**, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet* 2000; **356**: 1318-1321 [PMID: 11073021 DOI: 10.1016/s0140-6736(00)02816-6]

42 **Stanley AJ**, Ashley D, Dalton HR, Mowat C, Gaya DR, Thompson E, Warshow U, Groome M, Cahill A, Benson G, Blatchford O, Murray W. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. *Lancet* 2009; **373**: 42-47 [PMID: 19091393 DOI: 10.1016/s0140-6736(08)61769-9]

43 **McLaughlin C**, Vine L, Chapman L, Deering P, Whittaker S, Beckly J, Fortun P, Murray IA, Hussaini SH, Michell NP, Stableforth B, Thatcher P, Hare NC, Palmer J, Dalton HR. The management of low-risk primary upper gastrointestinal haemorrhage in the community: a 5-year observational study. *Eur J Gastroenterol Hepatol* 2012; **24**: 288-293 [PMID: 22189690 DOI: 10.1097/MEG.0b013e32834febef]

44 **Chen IC**, Hung MS, Chiu TF, Chen JC, Hsiao CT. Risk scoring systems to predict need for clinical intervention for patients with nonvariceal upper gastrointestinal tract bleeding. *Am J Emerg Med* 2007; **25**: 774-779 [PMID: 17870480 DOI: 10.1016/j.ajem.2006.12.024]

45 **Srirajaskanthan R**, Conn R, Bulwer C, Irving P. The Glasgow Blatchford scoring system enables accurate risk stratification of patients with upper gastrointestinal haemorrhage. *Int J Clin Pract* 2010; **64**: 868-874 [PMID: 20337750 DOI: 10.1111/j.1742-1241.2009.02267.x]

46 **Pang SH**, Ching JY, Lau JY, Sung JJ, Graham DY, Chan FK. Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. *Gastrointest Endosc* 2010; **71**: 1134-1140 [PMID: 20598244 DOI: 10.1016/j.gie.2010.01.028]

47 **Stanley AJ**, Dalton HR, Blatchford O, Ashley D, Mowat C, Cahill A, Gaya DR, Thompson E, Warshow U, Hare N, Groome M, Benson G, Murray W. Multicentre comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage. *Aliment Pharmacol Ther* 2011; **34**: 470-475 [PMID: 21707681 DOI: 10.1111/j.1365-2036.2011.04747.x]

48 **Le Jeune IR**, Gordon AL, Farrugia D, Manwani R, Guha IN, James MW. Safe discharge of patients with low-risk upper gastrointestinal bleeding (UGIB): can the use of Glasgow-Blatchford Bleeding Score be extended? *Acute Med* 2011; **10**: 176-181 [PMID: 22111089]

49 **Ahn S**, Lim KS, Lee YS, Lee JL. Blatchford score is a useful tool for predicting the need for intervention in cancer patients with upper gastrointestinal bleeding. *J Gastroenterol Hepatol* 2013; **28**: 1288-1294 [PMID: 23432611 DOI: 10.1111/jgh.12179]

50 **Romagnuolo J**, Barkun AN, Enns R, Armstrong D, Gregor J. Simple clinical predictors may obviate urgent endoscopy in selected patients with nonvariceal upper gastrointestinal tract bleeding. *Arch Intern Med* 2007; **167**: 265-270 [PMID: 17296882 DOI: 10.1001/archinte.167.3.265]

51 **Cheng DW**, Lu YW, Teller T, Sekhon HK, Wu BU. A modified Glasgow Blatchford Score improves risk stratification in upper gastrointestinal bleed: a prospective comparison of scoring systems. *Aliment Pharmacol Ther* 2012; **36**: 782-789 [PMID: 22928529 DOI: 10.1111/apt.12029]

52 **Stephens JR**, Hare NC, Warshow U, Hamad N, Fellows HJ, Pritchard C, Thatcher P, Jackson L, Michell N, Murray IA, Hyder Hussaini S, Dalton HR. Management of minor upper gastrointestinal haemorrhage in the community using the Glasgow Blatchford Score. *Eur J Gastroenterol Hepatol* 2009; **21**: 1340-1346 [PMID: 19738479 DOI: 10.1097/MEG.0b013e32831bc3ec]

53 **Mustafa Z**, Cameron A, Clark E, Stanley AJ. Outpatient management of low-risk patients with upper gastrointestinal bleeding: can we safely extend the Glasgow Blatchford Score in clinical practice? *Eur J Gastroenterol Hepatol* 2015; **27**: 512-515 [PMID: 25822859 DOI: 10.1097/meg.0000000000000333]

54 **Bryant RV**, Kuo P, Williamson K, Yam C, Schoeman MN, Holloway RH, Nguyen NQ. Performance of the Glasgow-Blatchford score in predicting clinical outcomes and intervention in hospitalized patients with upper GI bleeding. *Gastrointest Endosc* 2013; **78**: 576-583 [PMID: 23790755 DOI: 10.1016/j.gie.2013.05.003]

55 **Laursen SB**, Dalton HR, Murray IA, Michell N, Johnston MR, Schultz M, Hansen JM, Schaffalitzky de Muckadell OB, Blatchford O, Stanley AJ. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleeding. *Clin Gastroenterol Hepatol* 2015; **13**: 115-21.e2 [PMID: 25058843 DOI: 10.1016/j.cgh.2014.07.023]

56 **Masaoka T**, Suzuki H, Hori S, Aikawa N, Hibi T. Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention. *J Gastroenterol Hepatol* 2007; **22**: 1404-1408 [PMID: 17716345 DOI: 10.1111/j.1440-1746.2006.04762.x]

57 **Schiefer M**, Aquarius M, Leffers P, Stassen P, van Deursen C, Oostenbrug L, Jansen L, Masclee A, Keulemans YC. Predictive validity of the Glasgow Blatchford Bleeding Score in an unselected emergency department population in continental Europe. *Eur J Gastroenterol Hepatol* 2012; **24**: 382-387 [PMID: 22228368 DOI: 10.1097/MEG.0b013e3283505965]

58 **Laursen SB**, Hansen JM, Schaffalitzky de Muckadell OB. The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. *Clin Gastroenterol Hepatol* 2012; **10**: 1130-1135.e1 [PMID: 22801061 DOI: 10.1016/j.cgh.2012.06.022]

59 **Hyett BH**, Abougergi MS, Charpentier JP, Kumar NL, Brozovic S, Claggett BL, Travis AC, Saltzman JR. The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. *Gastrointest Endosc* 2013; **77**: 551-557 [PMID: 23357496 DOI: 10.1016/j.gie.2012.11.022]

60 **Chandra S**. AIMS65 score predicts short-term mortality but not the need for intervention in acute upper GI bleeding. *Gastrointest Endosc* 2013; **78**: 381-382 [PMID: 23867377 DOI: 10.1016/j.gie.2013.02.034]

61 **Nakamura S**, Matsumoto T, Sugimori H, Esaki M, Kitazono T, Hashizume M. Emergency endoscopy for acute gastrointestinal bleeding: prognostic value of endoscopic hemostasis and the AIMS65 score in Japanese patients. *Dig Endosc* 2014; **26**: 369-376 [PMID: 24168099 DOI: 10.1111/den.12187]

62 **Jung SH**, Oh JH, Lee HY, Jeong JW, Go SE, You CR, Jeon EJ, Choi SW. Is the AIMS65 score useful in predicting outcomes in peptic ulcer bleeding? *World J Gastroenterol* 2014; **20**: 1846-1851 [PMID: 24587662 DOI: 10.3748/wjg.v20.i7.1846]

63 **Yaka E**, Yılmaz S, Doğan NÖ, Pekdemir M. Comparison of the Glasgow-Blatchford and AIMS65 scoring systems for risk stratification in upper gastrointestinal bleeding in the emergency department. *Acad Emerg Med* 2015; **22**: 22-30 [PMID: 25556538 DOI: 10.1111/acem.12554]

64 **Masaoka T**, Suzuki H. Does the AIMS65, a new risk score for upper gastrointestinal bleeding, work in Japan? *Dig Endosc* 2014; **26**: 331-332 [PMID: 24754239 DOI: 10.1111/den.12224]

65 **Tammaro L**, Buda A, Di Paolo MC, Zullo A, Hassan C, Riccio E, Vassallo R, Caserta L, Anderloni A, Natali A. A simplified clinical risk score predicts the need for early endoscopy in non-variceal upper gastrointestinal bleeding. *Dig Liver Dis* 2014; **46**: 783-787 [PMID: 24953205 DOI: 10.1016/j.dld.2014.05.006]

66 **Cipolletta L**, Bianco MA, Rotondano G, Marmo R, Piscopo R. Outpatient management for low-risk nonvariceal upper GI bleeding: a randomized controlled trial. *Gastrointest Endosc* 2002; **55**: 1-5 [PMID: 11756905 DOI: 10.1067/mge.2002.119219]

67 **Attar A**, Sebbagh V, Vicaut E, Le Toumelin P, Bouhnik Y. Urgent endoscopy in severe non-variceal upper gastrointestinal hemorrhage: does the Glasgow-Blatchford score help endoscopists? *Scand J Gastroenterol* 2012; **47**: 1086-1093 [PMID: 22775006 DOI: 10.3109/00365521.2012.703237]

68 **Chandra S**, Hess EP, Agarwal D, Nestler DM, Montori VM, Song LM, Wells GA, Stiell IG. External validation of the Glasgow-Blatchford Bleeding Score and the Rockall Score in the US setting. *Am J Emerg Med* 2012; **30**: 673-679 [PMID: 21641145 DOI: 10.1016/j.ajem.2011.03.010]

69 **Wang CH**, Chen YW, Young YR, Yang CJ, Chen IC. A prospective comparison of 3 scoring systems in upper gastrointestinal bleeding. *Am J Emerg Med* 2013; **31**: 775-778 [PMID: 23465874 DOI: 10.1016/j.ajem.2013.01.007]

70 **Rockall TA**, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. *BMJ* 1995; **311**: 222-226 [PMID: 7627034]

71 **Das A**, Wong RC. Prediction of outcome of acute GI hemorrhage: a review of risk scores and predictive models. *Gastrointest Endosc* 2004; **60**: 85-93 [PMID: 15229431]

72 **Jairath V**, Kahan BC, Logan RF, Hearnshaw SA, Doré CJ, Travis SP, Murphy MF, Palmer KR. Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. *Endoscopy* 2012; **44**: 723-730 [PMID: 22752889 DOI: 10.1055/s-0032-1309736]

73 **Cooper GS**, Chak A, Way LE, Hammar PJ, Harper DL, Rosenthal GE. Early endoscopy in upper gastrointestinal hemorrhage: associations with recurrent bleeding, surgery, and length of hospital stay. *Gastrointest Endosc* 1999; **49**: 145-152 [PMID: 9925690]

74 **Lim LG**, Ho KY, Chan YH, Teoh PL, Khor CJ, Lim LL, Rajnakova A, Ong TZ, Yeoh KG. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. *Endoscopy* 2011; **43**: 300-306 [PMID: 21360421 DOI: 10.1055/s-0030-1256110]

75 **Lau JY**, Sung JJ, Chan AC, Lai GW, Lau JT, Ng EK, Chung SC, Li AK. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement study among international experts. *Gastrointest Endosc* 1997; **46**: 33-36 [PMID: 9260702]

76 **Farooq FT**, Lee MH, Das A, Dixit R, Wong RC. Clinical triage decision vs risk scores in predicting the need for endotherapy in upper gastrointestinal bleeding. *Am J Emerg Med* 2012; **30**: 129-134 [PMID: 21185674 DOI: 10.1016/j.ajem.2010.11.007]

77 **de Groot N**, van Oijen M, Kessels K, Hemmink M, Weusten B, Timmer R, Hazen W, van Lelyveld N, Vermeijden W, Baak L, Verburg R, Bosman J, de Wijkerslooth L, de Rooij J, Venneman N, Pennings M, van Hee K, Scheffer R, van Eijk R, Meiland R, Siersema P, Bredenoord A. Prediction scores or gastroenterologists' Gut Feeling for triaging patients that present with acute upper gastrointestinal bleeding. *United European Gastroenterol J* 2014; **2**: 197-205 [PMID: 25360303 DOI: 10.1177/2050640614531574]

78 **Jairath V**, Kahan BC, Stanworth SJ, Logan RF, Hearnshaw SA, Travis SP, Palmer KR, Murphy MF. Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. *Transfusion* 2013; **53**: 1069-1076 [PMID: 22897615 DOI: 10.1111/j.1537-2995.2012.03849.x]

79 **Ogino S**, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. *Am J Epidemiol* 2012; **176**: 659-667 [PMID: 22935517 DOI: 10.1093/aje/kws226]

80 **Ogino S**, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. *Mod Pathol* 2013; **26**: 465-484 [PMID: 23307060 DOI: 10.1038/modpathol.2012.214]

81 **Lochhead P**, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M, Ogino S. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. *Am J Gastroenterol* 2014; **109**: 1205-1214 [PMID: 24935274 DOI: 10.1038/ajg.2014.153]

82 **Ogino S**, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011; **60**: 397-411 [PMID: 21036793 DOI: 10.1136/gut.2010.217182]

**P-Reviewer:** Bustamante-Balen M, Ogino S **S-Editor:** Qiu S **L-Editor: E-Editor:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 1 Rockall score** | | | | |
| **Score**  **Variable** | **0** | **1** | **2** | **3** |
| Age | < 60 yr | 60-79 yr | ≥ 80 yr |  |
| Shock | No shock, systolic BP ≥ 100, pulse < 100 | Tachycardia, systolic BP ≥ 100, pulse ≥ 100 | Hypotension, systolic BP < 100 |  |
| Comorbidity | No major comorbidity |  | Cardiac failure, ischaemic heart disease, any major comorbidity | Renal failure, liver failure, disseminated malignancy |
| Diagnosis | Mallory-Weiss tear, no lesion identified and no SRH | All other diagnoses | Malignancy of UGI tract |  |
| Major SRH | None or dark spot only |  | Blood in UGI tract, adherent clot,  visible or spurting vessel |  |
| Admission score: Sum of age, shock and comorbidity; full score: Sum of age, shock, comorbidity, diagnosis and major SRH; BP: Blood pressure (measured in mmHg); UGI: Upper gastrointestinal; SRH: Stigmata of recent haemorrhage. | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 2 Baylor bleeding score** | | | | | |
|  | **1** | **2** | **3** | **4** | **5** |
| **Pre-endoscopy Score** |  | | | | |
| Age (yr) | 30-49 | 50-59 | 60-69 |  | > 70 |
| No. of illnesses | 1-2 |  |  | 3-4 | > 5 |
| Severity of illnesses |  |  |  | Chronic1 | Acute2 |
| Endoscopy Score |  | | | | |
| Site of bleeding |  |  |  | Posterior wall bulb |  |
| Stigmata of bleeding | Clot |  | Visible vessel | Active bleeding |  |

Pre-endoscopy score: Sum of the scores for age and the number and severity of concurrent illnesses; endoscopy score: Sum of the scores for site and stigmata of haemorrhage; post-endoscopy score: sum of the pre-endoscopy and endoscopy score; 1chronic: Presence of a concurrent chronic life-threatening illness; 2acute: Presence of a concurrent acute life-threatening illness.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3 Cedars-sinai medical centre predictive index** | | | | |
| Score | **EGD findings1** | **Time2** | **Haemodynamics** | **Comorbidities** |
| 0 | Ulcer without SHR, non-bleeding MW tear  Erosive disease, normal EGD | > 48 h | Stable | ≤ 1 |
| 1 | Ulcer with flat spot or clot, erosive disease with SHR, angiodysplasia | < 48 h | Intermediate | 2 |
| 2 | Ulcer with non- bleeding visible vessel or SHR | In hospital | Unstable | 3 |
| 3 |  |  |  | ≥ 4 |
| 4 | Persistent haemorrhage, varices  UGI cancer |  |  |  |

1Score for endoscopic findings was reduced by 1 point if effective endoscopic therapy was applied (not applicable to varices or cancer); 2Time from onset of symptoms to hospitalization; SHR: Stigmata of recent haemorrhage; MW: Mallory-Weiss tear; EGD: Esophagogastroduodenoscopy; UGI: Upper gastrointestinal.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 4 Progetto nazionale emorragia digestiva score** | | | | | | |
| Score | 1 | 2 | 3 | | 4 | |
| Variables | ASA 3  Time to  admission < 8 h | Hb level ≤ 7 g/dL  Age ≥ 80  Renal failure | | Rebleeding  ASA 4  Neoplasia  Liver cirrhosis | | Failure of endoscopic  treatment |
| ASA: American society of anaesthesiology; GI: Gastrointestinal. | | | | | | |

|  |  |
| --- | --- |
| **Table 5 Glasgow blatchford score** | |
| **Variable** | **Score** |
| Blood urea (mmol/L)  6.5-8  8-10  10-25  > 25 | 2  3  4  6 |
| Hb (g/L) for men  120-130  100-120  < 100 | 1  3  6 |
| Hb (g/L) for women  100-120  < 100  Systolic blood pressure (mmHg)  100-109  90-99  < 90  Pulse ≥ 100/min | 1  6  1  2  3  1 |
| History and comorbidities  Melaena  Syncope  Hepatic disease1  Cardiac failure2 | 1  2  2  2 |

|  |
| --- |
| 1Known history or clinical and laboratory evidence, of chronic or acute liver disease; 2Known history or clinical and echocardiographic evidence, of cardiac failure. |

|  |  |
| --- | --- |
| **Table 6 AIMS65 Score** | |
| **Variable** | **Score** |
| Albumin < 3 mg/dL | 1 |
| International normalized ratio > 1.5 | 1 |
| Systolic blood pressure < 90 mmHg | 1 |
| Altered mental status | 1 |
| Age > 65 yr | 1 |
|  | |
| |  |  |  |  | | --- | --- | --- | --- | | **Table 7 T-score** | | | | | **Score**  **Variable** | **1** | **2** | **3** | | General conditions | Poor | Intermediate | Good | | Pulse (beats/min) | > 110 | 90-110 | < 90 | | Systolic blood pressure (mmHg) | < 90 | 90-110 | > 110 | | Haemoglobin levels (g/dL) | ≤ 8 | 9-10 | > 10 | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 8 Outcomes** | | | | | | | |
| **Scores** |  |  |  | | **Primary outcome** |  | **Original studies** |
|  |  |  |  | |  |  |  |
| Endoscopy based score | | | | | | | |
| Forrest Classification | |  | | Rebleeding | |  | [[12](#_ENREF_12)] |
| BBS | |  | | Rebleeding | |  | [[19](#_ENREF_19)] |
| CSMCPI | |  | | Mean length of stay | |  | [[20](#_ENREF_20)] |
| Rockall | |  | | Mortality | |  | [[15](#_ENREF_15)] |
| PNED | |  | | Mortality | |  | [[21](#_ENREF_21)] |
| Clinical scores | | | | | | | |
| Clinical rockall | |  | | Mortality | |  | [[15](#_ENREF_15)] |
| GBS | |  | | Need intervention | |  | [[41](#_ENREF_41)] |
| AIMS65 | |  | | Mean length of stay/mortality | |  | [[23](#_ENREF_23)] |
| T-score | |  | | Time to endoscopy | |  | [[24](#_ENREF_24),[65](#_ENREF_65)] |
| BBS: Baylor bleeding score; CSMCPI: Cedars-sinai medical centre predictive index; PNED: Progetto nazionale emorragia digestiva; GBS: Glasgow blatchford score. | | | | | | | |